Purple Biotech (PPBT) Non-Current Assets (2015 - 2026)

Purple Biotech (PPBT) has 12 years of Non-Current Assets data on file, last reported at $7.6 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 72.8% year-over-year to $7.6 million in Q1 2026; TTM through Mar 2026 was $71.5 million, a 36.68% decrease from a year earlier, with the FY2025 full-year figure at $7.7 million, down 72.61% from the prior year.
• Non-Current Assets for Q1 2026 stood at $7.6 million, down from $7.7 million in the prior quarter.
• Over the last five years, Non-Current Assets for PPBT reached as high as $28.7 million in Q1 2023 and fell as low as $7.6 million in Q1 2026.
• Historically, Non-Current Assets has averaged $24.8 million across 5 years, with a median of $28.1 million in 2024.
• Across the five-year window, Non-Current Assets soared 33.46% in 2023 and slumped 72.8% in 2026, its largest moves.
• Year by year, Non-Current Assets stood at $21.4 million in 2022, then surged by 33.46% to $28.5 million in 2023, then retreated by 1.35% to $28.1 million in 2024, then sank by 72.61% to $7.7 million in 2025, then fell by 0.88% to $7.6 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $7.6 million in Q1 2026, $7.7 million in Q4 2025, and $28.3 million in Q3 2025.